RedHill Biopharma (RDHL) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
RedHill Biopharma has announced positive results from a Phase 3 study, showing that its RHB-104 treatment is 64% more effective than the standard of care alone for Crohn’s disease. The study, published in the peer-reviewed journal Antibiotics, demonstrated that RHB-104, an oral triple antimicrobial therapy, achieved a statistically significant higher clinical remission rate at week 26 compared to placebo. The company is poised to advance the development of RHB-104, potentially offering a new therapeutic approach for the debilitating inflammatory bowel disease.
For further insights into RDHL stock, check out TipRanks’ Stock Analysis page.